Earol Madrid Study

Cerumen Impaction of Both Ears Clinical Trial

— EMS  

Official title:

Multi-center, Open-label, Non-randomized, Single-arm Clinical Study to Assess the Safety and Performance of Earol® in Adult Patients With Ear Wax

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04653662
• Other study ID #: CD1620-001
• Status: Completed
• Phase: N/A
• Start date: December 3, 2019
• Est. completion date: January 26, 2022

Study information

• Verified date: March 2023
• Source: HL Healthcare Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Accumulation of ear wax in the external ear canal is a common pathology. The presence of ear wax not only interferes with the clinician's view of the tympanic membrane, but may also result in hearing loss and vertigo, and may predispose to ear infections.

Removal of ear wax is facilitated using a variety of cerumenolytics, or ear wax solvents. The current study is designed to evaluate the safety and the cerumenolytic effects of the Earol product, when dosed into the auditory canal prior to the dewaxing and ear cleaning procedure. This study is designed to be conducted in the primary care setting as a prospective clinical trial.

A detailed literature review has been conducted to provide a background summary of relevant information on the disease/pathology, other available treatment options and the pre-clinical testing and clinical research that has been conducted to date on the intended population or related populations and/or the device.

The aim for conducting this clinical investigation is to perform a PMCF to evaluate the safety and performance of Earol. Although there are alternative methods for ear wax removal, Earol represents a simple method based on natural ingredients (olive oil) which aids the removal of ear wax as well as prevents appearance of clinical symptoms in the ear canal (E.g. reducing itching and irritation).

Recruitment information / eligibility

• Status: Completed
• Enrollment: 108
• Est. completion date: January 26, 2022
• Est. primary completion date: June 17, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• Subject must be willing to provide written informed consent prior to any clinical investigation related procedure;

• Male or female patients over 18-year-old;

• Presence of ear wax in both ear canals with a minimum of > 50% ear wax blockage in at least one ear (level 4) and > 25% blockage in the contralateral ear (level 3) as assessed using the TMVSS;

• Subject must be willing and able to perform all the visits, follow the PI instructions and complete the follow-up of the study.

Exclusion Criteria:

• Subject is currently participating in another clinical investigation or has participated in another clinical investigation in the past 30 days prior to the start of the present study;

• Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period;

• Presence of other anatomic or comorbid conditions (e.g. ear eczema or seborrhea), or other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness;

• Presence or history of a tympanic membrane perforation or tympanostomy tubes at any time during the previous 6 months;

• Presence or history of a known or suspected ear infection (i.e. otitis externa or otitis interna) in the previous 2 months;

• Presence of a known or suspected chronic suppurative otitis media;

• Presence or history of a known or suspected keratosis obturans;

• Presence of known or suspected mastoiditis;

• Use of any ototopical drug or OTC product or ear wax-removal product (except for water or physiologic saline) during the preceding 3 days;

• Hypersensitivity to any product ingredient(s) or history of anaphylactic/anaphylactoid reactions;

• Temporal bone neoplasm.

Related Conditions & MeSH terms

• Cerumen Impaction of Both Ears

Intervention

Device:
• Earol
Treated with Earol on both ears and subsequent removal after 6 days of application

Locations

Country	Name	City	State
Spain	Clínica Universidad de Navarra	Madrid
Spain	Hospital QuironSalud Madrid	Madrid
Spain	Hospital Universitario de Getafe	Madrid
Spain	Hospital QuironSalud Marbella	Marbella
Spain	Hospital Quirónsalud Infanta Luisa	Sevilla

Sponsors (2)

Lead Sponsor	Collaborator
HL Healthcare Ltd	AKRN Scientific Consulting, S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SAEs and AEs reported	Adverse Events (AEs) and Serious Adverse Events (SAEs) post-treatment	Day 6
Secondary	Cerumen blockage assesment	Visualization of the tympanic membrane where cerumen blockage will be assessed post-treatment through the literature and protocol described tool TMVSS (Tympanic Membrane; Visualization Scoring System). This scale measures the level of obstruction of the ear canal by assessing the level of obstruction when trying to visualize the tympanic membrane with an otoscope.; Level of obstruction 1 - < 3 % Level of obstruction 2 - 3 - 25 % Level of obstruction 3 - 26 - 50 % Level of obstruction 4 - 51 - 75 % Level of obstruction 5 - 76 - 100 %	Day 0 and Day 6
Secondary	Ear clinical symptoms	Evaluate ear-specific clinical symptoms (e.g. dryness and itchiness) through a MD questionnaire. This scale has been specifically developed for this clinical trial.; - Clinical symptoms questionnaire (MD): Incidence of clinical symptoms and assessment scale of the intensity and frequency of the clinical symptoms (itchiness and dryness).	Day 0 and Day 6
Secondary	Patient clinical symptoms	Patient Questionnaire collecting clinical symptom prior and post-treatment This scale has been specifically developed for this clinical trial.; - Clinical symptoms questionnaire (patient): Incidence of clinical symptoms and assessment scale of the intensity and frequency of the clinical symptoms (itchiness and dryness).	Day 0 and Day 6
Secondary	SAEs and AEs reported	Adverse Events (AEs) and Serious Adverse Events (SAEs) post-treatment.	Day 12
Secondary	Patient clinical symptom and ease-of-use	Patient Questionnaire assessing the ease-of-use of the medical device (Earol). This scale has been specifically developed for this clinical trial.; - Ease of use of the device questionnaire: rating scale 0 - 10	Day 6